Joseph Monahan - Dec 15, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: ACRS
Transactions as of: Dec 15, 2022
Transactions value $: -$79,412
Form type: 4
Date filed: 12/16/2022, 03:57 PM
Previous filing: Oct 19, 2022
Next filing: Feb 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Sale	-$79.4K	-5K	-4.93%	$15.88	96.4K	Dec 15, 2022	Direct	F1, F2
holding	ACRS	Common Stock						193	Dec 15, 2022	By Spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.56 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.56 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.